Tue, May 11, 2021

Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Decreased Target to $170 on, May 11th, 2021

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-decreased-target-to-170-on-may-11th-2021.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $175 to $170 on, May 11th, 2021.

Raghuram has made no other calls on BTAI in the last 4 months.



There are 4 other peers that have a rating on BTAI. Out of the 4 peers that are also analyzing BTAI, 0 agree with Raghuram's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Raghuram


  • Anita Dushyanth of "Berenberg" Initiated at Strong Buy and Held Target at $75 on, Friday, April 9th, 2021
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $127 on, Thursday, April 1st, 2021
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $95 on, Thursday, April 1st, 2021
  • Colin Bristow of "UBS" Initiated at Strong Buy and Held Target at $99 on, Monday, February 1st, 2021